Trimeris late Thursday reported its fourth-quarter profit fell short of Wall Street estimates due to weaker sales of Fuzeon in North America. Goldman Sachs analyst Meg Malloy cut her estimates and price target on the company, saying new competition will hurt Fuzeon sales.
No comments:
Post a Comment